Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick P Zarrinkar

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Nature Reviews. Drug Discovery|April 12, 2008
High-throughput kinase profiling as a platform for drug discoveryDavid M Goldstein, Nathanael S Gray, Patrick P Zarrinkar
BMC Genomics|June 15, 2016
Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicineZhou Zhu, Nathan T Ihle, Paul A Rejto, et al.
Scientific Reports|September 27, 2018
An Internally Controlled Quantitative Target Occupancy Assay for Covalent InhibitorsRasmus Hansen, Sarah J Firdaus, Shuangwei Li, et al.
Nature Structural & Molecular Biology|May 16, 2018
The reactivity-driven biochemical mechanism of covalent KRAS<sup>G12C</sup> inhibitorsRasmus Hansen, Ulf Peters, Anjali Babbar, et al.
Nature Biotechnology|November 1, 2011
Comprehensive analysis of kinase inhibitor selectivityMindy I Davis, Jeremy P Hunt, Sanna Herrgard, et al.
Journal of the American Chemical Society|December 5, 2008
Tuning a three-component reaction for trapping kinase substrate complexesAlexander V Statsuk, Dustin J Maly, Markus A Seeliger, et al.
Chemistry & Biology|November 25, 2010
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistryLisa M Wodicka, Pietro Ciceri, Mindy I Davis, et al.
Cancer Research|January 21, 2006
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680Matthew A Young, Neil P Shah, Luke H Chao, et al.
Journal of Medicinal Chemistry|September 17, 2009
Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitorQi Chao, Kelly G Sprankle, Robert M Grotzfeld, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2015
Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitorsGang Liu, Sunny Abraham, Xing Liu, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Nature Reviews. Drug Discovery|April 12, 2008
High-throughput kinase profiling as a platform for drug discoveryDavid M Goldstein, Nathanael S Gray, Patrick P Zarrinkar
BMC Genomics|June 15, 2016
Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicineZhou Zhu, Nathan T Ihle, Paul A Rejto, et al.
Scientific Reports|September 27, 2018
An Internally Controlled Quantitative Target Occupancy Assay for Covalent InhibitorsRasmus Hansen, Sarah J Firdaus, Shuangwei Li, et al.
Nature Structural & Molecular Biology|May 16, 2018
The reactivity-driven biochemical mechanism of covalent KRAS<sup>G12C</sup> inhibitorsRasmus Hansen, Ulf Peters, Anjali Babbar, et al.
Nature Biotechnology|November 1, 2011
Comprehensive analysis of kinase inhibitor selectivityMindy I Davis, Jeremy P Hunt, Sanna Herrgard, et al.
Journal of the American Chemical Society|December 5, 2008
Tuning a three-component reaction for trapping kinase substrate complexesAlexander V Statsuk, Dustin J Maly, Markus A Seeliger, et al.
Chemistry & Biology|November 25, 2010
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistryLisa M Wodicka, Pietro Ciceri, Mindy I Davis, et al.
Cancer Research|January 21, 2006
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680Matthew A Young, Neil P Shah, Luke H Chao, et al.
Journal of Medicinal Chemistry|September 17, 2009
Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitorQi Chao, Kelly G Sprankle, Robert M Grotzfeld, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2015
Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitorsGang Liu, Sunny Abraham, Xing Liu, et al.
Pageof 2